Reg-D Private Placement: Accredited Investor Offering
IMPORTANT: Please read the risk section of the offer document carefully, risks include, but not limited too IPO assurances or success, clinical trial success, and Regulatory outcomes.
Invest in the Future of Healthcare Innovation
Medlab Group is pioneering advanced solutions in medical research and healthcare delivery. Our mission is to transform patient outcomes through cutting-edge technology and global partnerships.
This exclusive investment opportunity is available under Regulation D and is strictly limited to accredited investors.
Why Invest in Medlab?
Proven Expertise: A team of industry leaders driving innovation in healthcare.
Global Vision: Expanding across key markets with scalable solutions.
Growth Potential: Positioned for significant impact in a rapidly evolving sector.
Advanced Patented Technology: NanoCelle, 32 patents, multiple peer reviewed publications, and cornerstones the development of our new drug offerings.
Offering Highlights
Type: Private Placement under Reg-D, 506(c) exemption
Eligibility: Accredited Investors Only
Limited Availability: Immediate
Size: Up to $10M raise prices at $4 per share - with safeguards to guarantee ~50% to the anticipated IPO price
Minimum Parcel Size: $4,000 for 1,000 shares
Anticipated 2026 IPO: underwritten agreement for 1st 1/2 2026 IPO to NYSE
Questions, email: investors@medlab.group
Introducing NanoCelle:
How this patented drug delivery system reshapes and improves medicines
32 Granted Patents
4 Hi-Value R&D Programmes
25 Market Ready Assets
Strong R&D Portfolio across Oncology and age -related diseases, see our areas of therapeutic focus here.
Investor FAQ
-
Common Stock, priced at $4 per share
-
The purchase price is $4 per share, and the minimum parcel is size, is 1,000 shares. This means the minimum investment is $4,000.
-
Medlab is wanting to raise uo too $10,000,000
-
No, this is a private placement to accredited investors only: Reg-D offering. The company has an underwirtten agreement for an IPO first half of 2026. The IPO will be a public offering.
-
Accredited investor under the Reg-D offering will be able to acquire common stock at a 50% discount to the future IPO price.
-
The company is focused on:
Cancer induced pain, with potential extensions into broader pain topics
Chemotherapy indiced nasuea and vomiting
Muscle loss and recovery
cellulr health, and communication
the above covers significant global addressable markets with vast commercialisation potential.
For more information, see our areas of focus.
-
The company has a portfolio of approved nutraceuticals, to which the company intendes to licence and not self promote, these can be viewed here.
-
Please review the PPM, available here, or via the “Offering Documents” button above
-
Simply email us at investors@medlab.group cite your initial questions and we will schedule at time discuss further with relevant people.